Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2437 • ACR Convergence 2023
Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
Benjamin Cai¹, Rabina Giri², Helen Benham³, Linda Rehaume¹, Geoffery Strutton³, Anne-Sophie Bergot¹ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…
Abstract Number: L14 • ACR Convergence 2022
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos¹, Atul Deodhar², Désirée van der Heijde³, Marina Magrey⁴, Walter Maksymowych⁵, Tetsuya Tomita⁶, Huji Xu⁷, Marga Oortgiesen⁸, Ute Massow⁹, Carmen Fleurinck¹⁰, Alicia M Ellis⁸, Tom Vaux¹¹, Julie Shepherd-Smith¹¹, Alexander Marten⁹ and Lianne S Gensler¹², ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, ⁷Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), ⁸UCB Pharma, Morrisvile, NC, ⁹UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, ¹⁰UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
Abstract Number: 1151 • ACR Convergence 2022
Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
Alec Furst¹, John Davis¹, Manuel Rodriguez¹, Kimberly Ogle¹, James T. Rosenbaum² and Tejpal Gill¹, ¹OHSU, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is defined clinically as inflammatory back pain along with peripheral arthritis, and extra-articular manifestations involving the eye, gut, and skin. Even…
Abstract Number: 1514 • ACR Convergence 2022
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral for suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis in patients with chronic back pain (CBP).…
Abstract Number: 0372 • ACR Convergence 2022
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Kyung Min Ko¹ and Su-Jin Moon², ¹International St. Mary's Hospital, Incheon, Republic of Korea, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking The…
Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Philip J Mease¹, Atul Deodhar², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Helena Marzo-Ortega⁶, Martin Rudwaleit⁷, Christine de la Loge⁸, Alicia Ellis⁹, Carmen Fleurinck¹⁰, Marga Oortgiesen¹¹, Vanessa Taieb¹² and Lianne Gensler¹³, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University, University Hospitals, Richfield, OH, ⁶Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, ¹⁰UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Colombes, France, ¹³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…
Abstract Number: 0431 • ACR Convergence 2022
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Ana Lúcia Martins Fernandes¹, Ana Pinto², Kalveer flora³, dilpreet matharu³, anthony isaacs³ and Pedro Machado⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Local Health Unit of Guarda, Barcelos, Portugal, ³Northwick Park Hospital, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Biotherapeutics have revolutionized the treatment of axial spondyloarthritis (axSpA). The emergence of biosimilars allowed substantial savings and a wider access to treatment, and international…
Abstract Number: 1152 • ACR Convergence 2022
A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases
Helena Port¹, Walter P Maksymowych², Morten Karsdal³, Anne-Christine Bay-Jensen³ and Signe Holm Nielsen³, ¹University of Copenhagen, Copenhagen, Denmark, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: A hallmark of rheumatic joint diseases is altered cartilage protein turnover and protein composition. During cartilage erosions, the cartilage intermediate layer protein-1 (CILP-1), is…
Abstract Number: 1609 • ACR Convergence 2022
Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort
Paras Karmacharya¹, Cynthia Crowson², Ryan Lennon³, Dilli Poudel⁴, John Davis³, Alexis Ogdie⁵, Jean Liew⁶, Michael Ward⁷, Mariko Ishimori⁸, Michael Weisman⁹, Matthew Brown¹⁰, Mohammad Rahbar¹¹, Mark Hwang¹², John Reveille¹³ and Lianne Gensler¹⁴, ¹Vanderbilt University, Nashville, TN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN, ⁴Indiana Regional Medical Center, Indiana, PA, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Boston University, Boston, MA, ⁷National Institutes of Health, Rockville, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Genomics England, London, United Kingdom, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas McGovern Medical School, Houston, TX, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Comorbidities occur more frequently in patients with ankylosing spondylitis (AS) than in the general population and are associated with higher morbidity and mortality. Some…
Abstract Number: 0374 • ACR Convergence 2022
The BASDAI Index During Pregnancy
Olga Krichevskaya, Tatiana Dubinina, Ekaterina Ilinih, Svetlana Glukhova, Anastasia Demina and Irina Andrianova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: During pregnancy, BASDAI may reflect not only the activity of ankylosing spondylitis (AS), but also back pain and fatigue, that are associated with the…
Abstract Number: 0410 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Marina Magrey¹, Atul Deodhar², Philip J Mease³, Victoria Navarro-Compán⁴, Sofia Ramiro⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Vanessa Taieb⁹, Michael Frank Mørup¹⁰, Marga Oortgiesen¹¹ and Jonathan Kay¹², ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Colombes, France, ¹⁰UCB Pharma, Copenhagen, Denmark, ¹¹UCB Pharma, Raleigh, NC, ¹²Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…
Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Christina Charles-Schoeman¹, Ernest Choy², Iain B McInnes³, Eduardo Mysler⁴, Peter Nash⁵, Kunihiro Yamaoka⁶, Ralph Lippe⁷, Nasser Khan⁸, Anna K Shmagel⁹, Hannah Palac⁹, Jessica Suboticki¹⁰ and Jeffrey Curtis¹¹, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸AbbVie, Inc., Abbott Park, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰AbbVie, Inc., Mettawa, IL, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
Abstract Number: 1153 • ACR Convergence 2022
Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
Chan Mi Lee¹, Ricky Chan², Maricela Haghiac³ and Marina Magrey⁴, ¹University Hospitals, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Metrohealth Medical Center, Cleveland, OH, ⁴Case Western Reserve University, University Hospitals, Richfield, OH
Background/Purpose: Unlike most autoimmune diseases, ankylosing spondylitis (AS) is more frequently diagnosed in men (3:1) and with a higher radiographic progression compared to women. Th17…
Abstract Number: 1611 • ACR Convergence 2022
Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis
Thierry Sornasse¹, Liang Li², Shuang Zhao², Xiaohang Wang², Fang Cai³, Yingtao Bi⁴, In-Ho Song⁵, Stephanie Wichuk⁶, Robert G. Lambert⁷ and Walter P Maksymowych⁸, ¹AbbVie, South San Francisco, CA, ²The Metabolomics Innovation Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ³AbbVie, Redwood City, CA, ⁴AbbVie, Inc, Worcester, MA, ⁵AbbVie, Inc., North Chicago, IL, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Upadacitinib (UPA) 15 mg QD is efficacious in patients with active ankylosing spondylitis (AS) exhibiting inadequate responses to nonsteroidal anti-inflammatory drugs (NSAIDs-IR).1 We determined…
Abstract Number: 0375 • ACR Convergence 2022
The Presence of Heel Enthesitis on Physical Exploration Is Associated with Poorer Outcomes After 2 Years of Follow-up in Patients with Radiographic Axial Spondyloarthritis
Clementina Lopez-Medina¹, Maria Angeles Puche Larrubia², lourdes Ladehesa-Pineda³, Raquel Granados⁴, Pilar Font⁵ and Eduardo Collantes⁵, ¹Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁴Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain
Background/Purpose: Enthesitis represents one of the most important peripheral musculoskeletal manifestation in patients with axial Spondyloarthritis (axSpA). The prevalence and the burden of the disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].